Pfizer (PFE.US) has entered a clinical development collaboration to assess the effectiveness of a new drug combination in treating various solid tumors.

Summit Therapeutics, Inc. today announced a clinical trial collaboration with Pfizer (PFE.US) to evaluate the efficacy of ivonescimab, a dual-targeting PD-1/VEGF antibody, in combination with Pfizer's portfolio of antibody drug conjugates (ADCs) in treating various solid tumors.

Ivonescimab is a dual-targeting antibody that targets PD-1 and VEGF, originally developed by Kangtai Biologics. It blocks the binding of PD-1 to PD-L1 and PD-L2, as well as the binding of VEGF to its receptor. Kangtai Biologics (09926) public information indicates that, compared with combination therapy, the product may more effectively block these two signaling pathways by blocking both targets as a single drug, enhancing antitumor activity. Moreover, compared with combination therapy, ivonescimab has significant safety advantages, with a significant reduction in toxicity related to the VEGF target.

The major analysis of the phase 3 clinical trial HARMONi-2, which was presented at the 2024 World Conference on Lung Cancer (WCLC2024), showed that ivonescimab, as a first-line therapy, significantly reduced the risk of disease progression or death in patients with advanced non-small cell lung cancer (NSCLC) with positive PD-L1 expression, compared with approved heavyweight immune checkpoint inhibitors. It was listed as one of the top 10 R&D pipelines with potential blockbuster status in 2025 in the 2025 Biopharmaceutical Industry Trend Report released by industry media Evaluate at the beginning of this year.